|  |  |  |
| --- | --- | --- |
| REPUBLIQUE DU CAMEROUN  Paix - Travail - Patrie |  | REPUBLIC OF CAMEROON  Peace – Work – Fatherland |
| -------------------------- | -------------------------- |
| MINISTERE DE LA SANTE PUBLIQUE  -------------------------- | MINISTRY OF PUBLIC HEALTH  -------------------------- |
| SECRETARIAT GENERAL  -------------------------- | SECRETARIAT GENERAL  -------------------------- |
| **DIRECTION DE LA PHARMACIE, DU MEDICAMENT ET DES LABORATOIRES**  -------------------------- | **DEPARTMENT OF PHARMACY, DRUGS AND LABORATORIES**  -------------------------- |
| SOUS-DIRECTION DE LA PHARMACIE  ------------------------- | SUB-DEPARTMENT OF PHARMACY  ------------------------- |
| Service des Normes et de la Législation pharmaceutiques  ------------------------- |  | Service for Pharmaceuticals Norms and Legislation  ------------------------- |
|  |  |  |
|  | |  |

**FICHE DE CONTRÔLE DE GESTION ET DE COLLECTE DES DONNEES STATISTIQUES**

**SUR LA CONSOMMATION DES STUPEFIANTS ET DES PSYCHOTROPES**

**DATE DE DESCENTE SUR LE TERRAIN :………………………………………………………………………………………………………………..**

**PERIODE DE COLLECTE : …………………………………………………………………………………………………………………………………….**

**REGION :……………………………………….. DEPARTEMENT :……………………………… DISTRICT DE SANTE :……………………………..**

**NOM DE LA STRUCTURE : ……………………………………………………………………………………………………………………………………**

**RESPONSABLE DE LA STRUCTURE VISITEE :…………………………………………………………………………………………………………….**

**RESPONSABLE DE LA PHARMACIE : …………………………………………………GRADE/ FONCTION :…………………………………………**

**TELEPHONE : …………………………………………………… ADRESSE/ E.MAIL : ……………………………………………………………………..**

STUPEFIANTS

| **DCI** | **DESIGNATIONS /SPECIALITES** | **PRESENTATION**  **FORME/ DOSAGE** | **QUANTITE REÇUE** | **QUANTITE DU PRINCIPE ACTIF (EN gramme)** | **LABORATOIRE FABRICANT / PAYS** | **BENEFICIAIRES** | **OBSERVATIONS** | **DCI** | **DESIGNATIONS/ SPECIALITES** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| BUPRENORPHINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| CODEINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| DEXTROMORAMIDE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| FENTANYL |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| HYDROCODONE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| LEVOMETHORPHONE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| LEVOMORAMIDE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| METHADONE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| MORPHINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| PENTAZOCINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| PETHIDINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| PHOLCODINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| SUFENTANIL |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

NB : En observation, bien vouloir ressortir les quantités distribuées et consommées sans omettre le stock disponible, utilisable et la quantité des périmés. /-

**AUTRES A SPECIFIER**

| **N°** | **DCI** | **DESIGNATIONS /SPECIALITES** | **PRESENTATION**  **FORME/ DOSAGE** | **QUANTITE REÇUE** | **QUANTITE DU PRINCIPE ACTIF (EN gramme)** | **LABORATOIRE FABRICANT / PAYS** | **BENEFICIAIRES** | **OBSERVATIONS** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

NB : En observation, bien vouloir ressortir les quantités distribuées et consommées sans omettre le stock disponible, utilisable et la quantité des périmés. /-

PSYCHOTROPES

| **DCI** | **DESIGNATIONS /SPECIALITES** | **PRESENTATION**  **FORME/ DOSAGE** | **QUANTITE REÇUE** | **QUANTITE DU PRINCIPE ACTIF (EN gramme)** | **LABORATOIRE FABRICANT / PAYS** | **BENEFICIAIRES** | **OBSERVATIONS** | **DCI** | **DESIGNATIONS/ SPECIALITES** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ACIDE VALPROÏQUE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| ALPRAZOLAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| AMOXAPINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| AMYTRIPTILYNE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| BROMAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| CARBAMAZEPINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| CHLORPROMAZINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| CLOBAZAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| CLOMIPRAMINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| CLONAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| CLORAZEPATE DIPOTASSIQUE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| DIAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| DROPERIDOL |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| FLUOXETINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| FLUPHENAZINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| HALOPERIDOL |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| LEVOPROMAZINE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| LOFLAZEPATE D'ETHYLE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| LOPRAZOLAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| LORAMETAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| LORAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| MEPROBAMATE |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| MIDAZOLAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| NITRAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| NORDAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| OXAZEPAM |  |  |  |  |  |  |  |  |  |
| PHENOBARBITAL |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| PRAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| TETRAZEPAM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| ZOLPIDEM |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

**AUTRES A SPECIFIER**

| **N°** | **DCI** | **DESIGNATIONS/SPECIALITES** | **PRESENTATION**  **FORME/DOSAGE** | **QUANTITE REÇUE** | **QUANTITE DU PRINCIPE ACTIF (EN GRAMME)** | **LABORATOIRE FABRICANT/ PAYS** | **BENEFICIAIRES** | **OBSERVATIONS** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |

**NB : En observation, bien vouloir ressortir les quantités distribuées et consommées sans omettre le stock disponible, utilisable et la quantité des périmés. /-**

**RENSEIGNEMENTS GENERAUX SUR LA GESTION DES STUPEFIANTS ET DES PSYCHOTROPES**

|  |  |  |
| --- | --- | --- |
| **QUESTIONS** | **OUI** | **NON** |
| Existe –il un fichier fournisseur ? |  |  |
| Existe –il un registre des entrées ? |  |  |
| Existe –il un registre des sorties ? |  |  |
| Existe –il des fiches de suivi de ce type de patients ? |  |  |
| Existe –il des fiches de stock (disponibles ou périmés) ? |  |  |
| Existe –il des fiches d’inventaire ? |  |  |
| Existe –il des bons de commande ? |  |  |
| Existe –il des bordereaux de livraison ? |  |  |
| Existe –il un fichier clients ? |  |  |

**COMMENTAIRES SUR :**

Périmés : \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Outils de gestion :\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Condition de stockage :\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**OBSERVATIONS GENERALES :**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**NOMS ET SIGNATURES DES MEMBRES DE L’EQUIPE DE MISSION**